I heard about this company a few months ago when Tommy Tuberville, who is on the Armed Services Committee, bought some. It reeked of insider training because the company had sent their HAV (human acellular vessel) technology to Ukraine under compassionate use.

Reportedly, it worked well and the experience in Ukraine is part of their application for a biological license; the action date is August 10th.

The stock price has been going up quickly and I added to my position today. After I bought more it went up 5 more percent (a total of 6% for the day).

It’s a pre revenue company so there is the associated risk. It’s promising, however, and might be a consideration for a small position. The ticker is HUMA. Here is the website:

https://humacyte.com